NASDAQ:MYL - Mylan Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.50 -0.10 (-0.38 %) (As of 04/24/2019 10:37 AM ET)Previous Close$26.60Today's Range$26.41 - $26.7752-Week Range$26.00 - $42.50Volume29,467 shsAverage Volume5.26 million shsMarket Capitalization$13.67 billionP/E Ratio5.79Dividend YieldN/ABeta1.48 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Receive MYL News and Ratings via Email Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MYL Previous Symbol CUSIP62853010 CIK1623613 Webwww.mylan.com Phone44-0-17-0785-3000Debt Debt-to-Equity Ratio1.17 Current Ratio1.39 Quick Ratio0.83Price-To-Earnings Trailing P/E Ratio5.79 Forward P/E Ratio6.05 P/E Growth1.13 Sales & Book Value Annual Sales$11.43 billion Price / Sales1.20 Cash Flow$8.5761 per share Price / Cash Flow3.09 Book Value$23.60 per share Price / Book1.12Profitability EPS (Most Recent Fiscal Year)$4.58 Net Income$352.50 million Net Margins3.08% Return on Equity19.06% Return on Assets7.03%Miscellaneous Employees35,000 Outstanding Shares515,950,000Market Cap$13.67 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Mylan (NASDAQ:MYL) Frequently Asked Questions What is Mylan's stock symbol? Mylan trades on the NASDAQ under the ticker symbol "MYL." How were Mylan's earnings last quarter? Mylan NV (NASDAQ:MYL) issued its earnings results on Tuesday, February, 26th. The company reported $1.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by $0.06. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.10 billion. Mylan had a net margin of 3.08% and a return on equity of 19.06%. The firm's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period last year, the business posted $1.43 EPS. View Mylan's Earnings History. When is Mylan's next earnings date? Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Mylan. What guidance has Mylan issued on next quarter's earnings? Mylan issued an update on its FY19 earnings guidance on Tuesday, February, 26th. The company provided earnings per share (EPS) guidance of $3.80-4.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.02. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.87 billion.Mylan also updated its FY 2019 guidance to $3.80-4.80 EPS. What price target have analysts set for MYL? 20 brokers have issued 12 month price targets for Mylan's stock. Their predictions range from $31.00 to $59.00. On average, they expect Mylan's stock price to reach $40.2222 in the next year. This suggests a possible upside of 52.1% from the stock's current price. View Analyst Price Targets for Mylan. What is the consensus analysts' recommendation for Mylan? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan. What are Wall Street analysts saying about Mylan stock? Here are some recent quotes from research analysts about Mylan stock: 1. Cantor Fitzgerald analysts commented, ". We are lowering our 1Q19 EPS estimate for MYL to $0.70 from $0.88. The decrease in our estimate is based on comments the company made at a conference on 3/5/19. This does not affect our investment thesis, and we are thus maintaining our Neutral rating and 12-month PT of $41." (4/1/2019) 2. According to Zacks Investment Research, "Mylan’s fourth-quarter results were disappointing as the company missed on both earnings and sales. With the generic market experiencing a slowdown, Mylan itself proactively discontinued a number of products along with transferring some to other sites. These have led to a temporary disruption in supply of certain products and reduced volumes in North America generic sales. The FDA approved rival Teva Pharmaceutical’s generic version of EpiPen and EpiPen Jr, which, in turn, will negatively impact sales further. Moreover, slower-than-expected uptake of generic Copaxone, even after reducing the price by more than 60%, adversely impacted sales in North America. The guidance for 2019 was disappointing as well. Nevertheless, Mylan received a significant boost when the FDA approved its generic version of Advair Diskus — Wixela Inhub — following a few setbacks. Shares have underperformed the industry in the last six months." (3/6/2019) Has Mylan been receiving favorable news coverage? Headlines about MYL stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mylan earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the near future. Are investors shorting Mylan? Mylan saw a increase in short interest in March. As of March 15th, there was short interest totalling 11,829,580 shares, an increase of 62.9% from the February 28th total of 7,261,427 shares. Based on an average trading volume of 7,172,065 shares, the short-interest ratio is presently 1.6 days. Approximately 2.3% of the company's stock are sold short. View Mylan's Current Options Chain. Who are some of Mylan's key competitors? Some companies that are related to Mylan include Shire (SHPG), Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF) and GRIFOLS S A/S (GRFS). What other stocks do shareholders of Mylan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Alibaba Group (BABA), Allergan (AGN), Starbucks (SBUX), Micron Technology (MU), QUALCOMM (QCOM), General Electric (GE), Intel (INTC) and Celgene (CELG). Who are Mylan's key executives? Mylan's management team includes the folowing people: Ms. Heather Bresch, CEO & Exec. Director (Age 50)Mr. Rajiv Malik, Pres & Exec. Director (Age 58)Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 46)Mr. Anthony Mauro, Chief Commercial Officer (Age 46) Who are Mylan's major shareholders? Mylan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.71%), Retirement Systems of Alabama (0.05%), RPG Investment Advisory LLC (0.04%), Strs Ohio (0.03%), Nisa Investment Advisors LLC (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan. Which institutional investors are selling Mylan stock? MYL stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Strs Ohio, Virtu Financial LLC, Sumitomo Life Insurance Co., Bank of The West, Horan Capital Advisors LLC., Gateway Investment Advisers LLC and Kanawha Capital Management LLC. View Insider Buying and Selling for Mylan. Which institutional investors are buying Mylan stock? MYL stock was bought by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Clear Harbor Asset Management LLC, Regent Investment Management LLC, Nisa Investment Advisors LLC, Investors Research Corp, RPG Investment Advisory LLC, State of Alaska Department of Revenue and Retirement Systems of Alabama. View Insider Buying and Selling for Mylan. How do I buy shares of Mylan? Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mylan's stock price today? One share of MYL stock can currently be purchased for approximately $26.45. How big of a company is Mylan? Mylan has a market capitalization of $13.65 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe. What is Mylan's official website? The official website for Mylan is http://www.mylan.com. How can I contact Mylan? Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected] MarketBeat Community Rating for Mylan (NASDAQ MYL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 676 (Vote Outperform)Underperform Votes: 533 (Vote Underperform)Total Votes: 1,209MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is a front-end load?